F
Furhan Yunus
Researcher at University of Tennessee
Publications - 18
Citations - 2232
Furhan Yunus is an academic researcher from University of Tennessee. The author has contributed to research in topics: Induction chemotherapy & Follicular lymphoma. The author has an hindex of 12, co-authored 16 publications receiving 2067 citations. Previous affiliations of Furhan Yunus include University of Nebraska–Lincoln & University Of Tennessee System.
Papers
More filters
Book
Non-Hodgkin's Lymphomas
Andrew D. Zelenetz,Ranjana H. Advani,John C. Byrd,Myron S. Czuczman,Lloyd E. Damon,Madeleine Duvic,Luis Fayad,Andres Forero,Martha Glenn,Jon P. Gockerman,Leo I. Gordon,Nancy L. Harris,Richard T. Hoppe,Steven M. Horwitz,Mark S. Kaminski,Youn H. Kim,Ann S. LaCasce,A P Nademanee,Elise Olsen,Pierluigi Porcu,Oliver W. Press,Leonard R. Prosnitz,Mitchell R. Smith,Eduardo M. Sotomayor,Julie M. Vose,Joachim Yahalom,Furhan Yunus +26 more
TL;DR: In this article, different subtypes of non-Hodgkin's lymphoma (NHL) were compared using histological and immunohistochemical methods, including the normal lymph node structure and function.
Journal ArticleDOI
Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer
Ezra E.W. Cohen,Theodore Karrison,Masha Kocherginsky,Jeffrey Mueller,Robyn Egan,Chao H. Huang,Bruce Brockstein,Mark Agulnik,Bharat B. Mittal,Furhan Yunus,Sandeep Samant,Luis E. Raez,Ranee Mehra,Priya Kumar,Frank G. Ondrey,Patrice Marchand,Bettina Braegas,Tanguy Y. Seiwert,Victoria M. Villaflor,Daniel J. Haraf,Everett E. Vokes +20 more
TL;DR: The study was underpowered because it did not meet the planned accrual target, and OS was higher than predicted in both arms, but IC cannot be recommended routinely in patients with N2 or N3 locally advanced SCCHN.
Journal ArticleDOI
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Andrew D. Zelenetz,Jeremy S. Abramson,Ranjana H. Advani,Charalambos Andreadis,John C. Byrd,Myron S. Czuczman,Luis Fayad,Andres Forero,Martha Glenn,Jon P. Gockerman,Leo I. Gordon,Nancy L. Harris,Richard T. Hoppe,Steve Horwitz,Mark S. Kaminski,Youn H. Kim,Ann S. LaCasce,Tariq I Mughal,A P Nademanee,Pierluigi Porcu,Oliver W. Press,Leonard R. Prosnitz,Nishitha Reddy,Matthew R. Smith,Lubomir Sokol,Lode J. Swinnen,Julie M. Vose,William G. Wierda,Joachim Yahalom,Furhan Yunus +29 more
Journal ArticleDOI
NCCN clinical practice guidelines in oncology: multiple myeloma.
Kenneth C. Anderson,M. Alsina,William I. Bensinger,Biermann Js,Asher A. Chanan-Khan,Adam D. Cohen,Steven M. Devine,Benjamin Djulbegovic,Cristina Gasparetto,Carol Ann Huff,Madan Jagasia,Bruno C. Medeiros,Ruby F. Meredith,Noopur Raje,Jeffrey Schriber,Seema Singhal,George Somlo,Keith Stockerl-Goldstein,Guido Tricot,Julie M. Vose,Donna M. Weber,Joachim Yahalom,Furhan Yunus +22 more
Journal ArticleDOI
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Renato G. Martins,Upendra Parvathaneni,Julie E. Bauman,Anand K. Sharma,Luis E. Raez,Michael A. Papagikos,Furhan Yunus,Brenda F. Kurland,Keith D. Eaton,Jay J. Liao,Eduardo Mendez,Neal D. Futran,David X. Wang,Xiaoyu Chai,Sarah G. Wallace,Melissa A. Austin,Rodney A. Schmidt,D. Neil Hayes +17 more
TL;DR: Erlotinib did not increase the toxicity of cisplatin and radiotherapy in patients with locally advanced HNSCC but failed to significantly increase CRR or PFS.